TNF and infection: Overall, we did not observe any significant differences in the risk of serious infections between patients treated with vedolizumab and patients treated with TNF antagonists in the 1:1 propensity score–matched cohort (1-year risk, 8.2% vs 8.7%; adjusted HR, 1.04; 95% CI, 0.58-1.85) (Table 2).